Pearl Meyer

ARTICLE | NOV 2025

Three Emerging Themes in Life Sciences Executive Pay for 2026



Will Cockle

MANAGING DIRECTOR

The life sciences industry is entering 2026 amid ongoing transformation. Recent outlooks highlight accelerating innovation and AI adoption, steady demand, tightening capital markets, and continued competition for specialized talent. Companies are responding with a renewed focus on efficiency, partnerships, and long-term resilience.

For the first time, Pearl Meyer's annual *Looking Ahead to Executive Pay Practices* study includes a dedicated life sciences industry cut. The findings reveal how boards are translating these market pressures into executive pay strategy, connecting compensation design to the sector's distinctive mix of innovation, regulation, and leadership risk. The result is a boardroom-level view that moves beyond broad market commentary.

Within this new analysis, three themes emerge that define how life sciences organizations are approaching executive compensation for 2026: cautious recovery and focused stability, targeted investment in critical talent, and fine-tuning performance alignment.

Theme #1: Cautious Recovery and Focused Stability

After several turbulent years, life sciences organizations are approaching 2026 with measured optimism. Boards are showing confidence that operations and funding are stabilizing, while remaining realistic about ongoing risks. Most life sciences companies expect 2025 performance to be stable or modestly better than the prior year, signaling recovery from recent volatility rather than a surge in growth. Across the broader market, organizations report similar expectations, underscoring a shared emphasis on stability over expansion.

Life sciences firms are maintaining disciplined salary budgets, with 2026 projections slightly below 2025 levels but still above pre-pandemic norms, while avoiding major incentive plan redesigns. The majority anticipate incentive payouts near or just below target levels, reflecting confidence in operational progress tempered by the realities of

milestone-driven business cycles.

Boards are also being measured in their use of discretion. While the majority of companies are taking a wait and see approach, only a small minority anticipate making positive adjustments to incentive payouts and the overall use of discretion is expected to be remain consistent with 2024 levels.

Taken together, these patterns illustrate a sector that relies on durable pay programs as a strategic lever, supporting leadership continuity and signaling to investors that long-term focus, not short-term volatility, drives decision-making.

Theme #2: Targeted Investment in Critical Talent

In this environment, compensation strategies are becoming more measured and differentiated. Most life sciences organizations report total compensation targets above market medians, reflecting the sector's ongoing competition for experienced leadership talent. While many companies are maintaining broad pay competitiveness, boards are also placing particular emphasis on roles where expertise most directly advances innovation, regulatory progress, and commercialization success.

Some organizations are also using supplemental or off-cycle equity grants as targeted retention tools. This practice is more common in life sciences than in the broader market, underscoring how companies in this sector prioritize retaining pivotal leaders through key development and approval milestones. These practices reflect a sector that recognizes maintaining key talent as essential to discovery, innovation, and long-term success.

Stability begins with leadership, and life sciences companies know how difficult it is to retain the scientific and regulatory expertise their success depends on. Yet, succession preparedness remains uneven across the sector. Nearly two-thirds of life sciences organizations report having only emergency CEO succession plans or none at all. This gap presents an opportunity for boards to take a more proactive approach to leadership continuity, ensuring that the investment in talent today supports sustained innovation and performance over the long term.

Theme #3: Fine-Tuning Performance Alignment

Milestone-based incentives have long been central to life sciences pay design, reflecting how progress unfolds through research, regulatory approvals, and partnerships rather than quarter-to-quarter financials. That foundation remains in place, but boards are putting greater emphasis on precision and oversight in how performance is defined and evaluated.

Across the survey, most companies are keeping their incentive structures consistent for 2026. In life sciences, the focus is on refining and clarifying existing measures so that goals are specific, measurable, and linked to long-term value creation. As noted in the first theme, bonuses are generally anticipated to pay out near target with limited discretion,

suggesting that programs are functioning as intended. Boards are using this environment of relative stability to fine-tune how success is defined and evaluated. Compensation committees are taking a more active role in reviewing goal-setting practices, ensuring thresholds and targets are well calibrated and that the rationale for outcomes is clearly documented.

In an industry where a single regulatory approval or clinical milestone can transform a company's valuation, boards are paying closer attention to the measurable performance drivers that lead up to those events. Incentive plans emphasize concrete objectives such as operational efficiency, financial progress, and program advancement, helping keep expectations clear and objective while maintaining alignment with the milestones that ultimately define enterprise value.

A More Mature Model for Executive Pay

Together, these three themes (stability, selectivity, and refined performance alignment) signal that the life sciences industry is entering a new phase of maturity in executive compensation.

Boards are using pay as a strategic tool for resilience, not a reactive response to market swings. For life sciences companies, 2026 will be a year of intentional calibration, aligning pay with performance to sustain innovation.

To explore the full Life Sciences data set and see how your organization compares, contact Pearl Meyer. An Executive Summary of the Looking Ahead to Executive Pay Practices in 2026 report is available on the Pearl Meyer website; the complete report is available for purchase.

About the Author

Will specializes in executive compensation for technology and life sciences companies, from startups to public firms, with deep expertise in IPO preparation and equity strategy transitions.

About Pearl Meyer

Pearl Meyer is the leading advisor to boards and senior management helping organizations build, develop, and reward great leadership teams that drive long-term success. Our strategy-driven compensation and leadership consulting services act as powerful catalysts for value creation and competitive advantage by addressing the critical links between people and outcomes. Our clients stand at the forefront of their industries and range from emerging high-growth, not-for-profit, and private organizations to the Fortune 500.

Three Emerging Themes in Life Sciences Executive Pay for 2026 | pearlmeyer.com